1. Hanssen, De Vos and Nieuwdorp, Cell Metabolism, 2021. Fecal microbiota transplantation in human metabolic diseases: From a murky past to a bright future?
  2. De Clercq et al. CCR, 2021. Fecal Microbiota Transplantation from Overweight or Obese Donors in Cachectic Patients with Advanced Gastroesophageal Cancer: A Randomized, Double-blind, Placebo-controlled, Phase II Study
  3. De Groot et al. Gut, 2020. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomized controlled trial
  4. Witjes et al. Hepatology Communications, 2020. Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals with Steatohepatitis
  5. Rouanet et al. Frontiers in Medicine, 2020. Live Biotherapeutic Products, A Road Map for Safety Assessment**
  6. Mikkelsen et al. UEG Journal, 2020. Towards an EU-wide suitable regulatory framework for faecally derived, industrially manufactured medicinal products**
  7. Gilijamse et al. NPJ Biofilms and Microbiomes 2020: Treatment with E. hallii *: a pilot study of safety and dose-response effects on glucose metabolism in human subjects with metabolic syndrome
  8. Li et al, Science 2016, Durable coexistence of donor and recipient strains after fecal microbiota transplantation
  9. Bui et al, Nature Communications 2015, Production of butyrate from lysine and the Amadori product fructoselysine by a human gut commensal
  10. Udayappan et al, CEI 2014, Intestinal microbiota and faecal transplantation as treatment modality for insulin resistance and type 2 diabetes mellitus
  11. Vrieze et al, Gastroenterol 2012, Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with Metabolic Syndrome

* Eubacterium hallii has been renamed Anaerobutyricum soehngenii